Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results
Aim. Demonstration the possibility of practical application of the highly sensitive tumor marker CA-62 in the initial diagnosis in asymptomatic patients with suspected cancer and/or the presence of pathological changes in instrumental studies, as well as describe the criteria for interpreting the re...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2023-06-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/622995/138829 |
| _version_ | 1797506045079191552 |
|---|---|
| author | Janneta R. Tcherkassova Sergei A. Tsurkan Anna I. Prostyakova Nikolai V. Suganov Alexander M. Boroda Albina I. Khamitova Alexander P. Roytman |
| author_facet | Janneta R. Tcherkassova Sergei A. Tsurkan Anna I. Prostyakova Nikolai V. Suganov Alexander M. Boroda Albina I. Khamitova Alexander P. Roytman |
| author_sort | Janneta R. Tcherkassova |
| collection | DOAJ |
| description | Aim. Demonstration the possibility of practical application of the highly sensitive tumor marker CA-62 in the initial diagnosis in asymptomatic patients with suspected cancer and/or the presence of pathological changes in instrumental studies, as well as describe the criteria for interpreting the results to help the doctor make a decision.
Materials and methods. The article used the results and conclusions of blind clinical trials conducted to detect early stages of breast cancer (BC), prostate cancer (PC), colorectal cancer (CRC) and non-small cell lung cancer using the CA-62 tumor marker and other tumor markers. Statistical analysis was performed using the MedCalc program (MedCalc Software Ltd, Belgium). Diagnostic efficiency was assessed in terms of sensitivity, specificity, test accuracy, PPV and NPV, ROC analysis. The significance level was taken as p0.001.
Results. The use of the standard cut-off value of 5000 U/ml of the CA-62 tumor marker makes it possible to achieve 97% sensitivity with 95% specificity in stage I BC. The combination of tumor markers CA-62 and CA 15-3 allows achieving 100% specificity in differentiation of BC and benign breast hyperplasia. The use of the CA-62 marker (6500 U/ml) in the gray zone of PSA 2.510 ng/ml improves the accuracy of detecting PC in biopsy from 35 to 93.1% with 90% sensitivity and 97% specificity. The use of a combination of tumor markers (CA-625000 U/ml, CYFRA 21-12.5 ng/ml and CEA5 ng/ml) will allow the doctor to improve the efficiency of differentiating lung cancer from chronic obstructive pulmonary disease. The combined use of markers (CEA3.5 ng/ml) and (CA-625000 U/ml) achieves 100% specificity with 97% sensitivity in detecting early stages of CRC.
Conclusion. The article shows the possibilities of using the CA-62 marker, as well as new algorithms for the detection and differentiation of early stages of BC, PC, non-small cell lung cancer and CRC and benign neoplasms using the CA-62 marker in primary diagnosis. The use of the CA-62 tumor marker or its combination with other diagnostic methods can be a useful strategy for a comprehensive assessment of the risk of malignant neoplasms and increasing the diagnostic sensitivity of detecting early stages of cancer. |
| first_indexed | 2024-03-10T04:26:59Z |
| format | Article |
| id | doaj.art-a3f05b75156942f5a37c275d6bcaad40 |
| institution | Directory Open Access Journal |
| issn | 2075-1753 2542-2170 |
| language | Russian |
| last_indexed | 2024-03-10T04:26:59Z |
| publishDate | 2023-06-01 |
| publisher | ZAO "Consilium Medicum" |
| record_format | Article |
| series | Consilium Medicum |
| spelling | doaj.art-a3f05b75156942f5a37c275d6bcaad402023-11-23T06:48:52ZrusZAO "Consilium Medicum"Consilium Medicum2075-17532542-21702023-06-0125640641410.26442/20751753.2023.6.2023074737Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the resultsJanneta R. Tcherkassova0https://orcid.org/0000-0002-9074-7233Sergei A. Tsurkan1https://orcid.org/0000-0002-0030-1802Anna I. Prostyakova2https://orcid.org/0000-0001-5922-6600Nikolai V. Suganov3Alexander M. Boroda4https://orcid.org/0000-0002-4196-6042Albina I. Khamitova5Alexander P. Roytman6https://orcid.org/0000-0003-2592-6857“JVS Diagnostics„ LLC“JVS Diagnostics„ LLCShemyakin–Ovchinnikov Institute of Bioorganic Chemistry“JVS Diagnostics„ LLCSechenov First Moscow State Medical University (Sechenov University)Kazan National Research Technological UniversityRussian Medical Academy of Continuous Professional EducationAim. Demonstration the possibility of practical application of the highly sensitive tumor marker CA-62 in the initial diagnosis in asymptomatic patients with suspected cancer and/or the presence of pathological changes in instrumental studies, as well as describe the criteria for interpreting the results to help the doctor make a decision. Materials and methods. The article used the results and conclusions of blind clinical trials conducted to detect early stages of breast cancer (BC), prostate cancer (PC), colorectal cancer (CRC) and non-small cell lung cancer using the CA-62 tumor marker and other tumor markers. Statistical analysis was performed using the MedCalc program (MedCalc Software Ltd, Belgium). Diagnostic efficiency was assessed in terms of sensitivity, specificity, test accuracy, PPV and NPV, ROC analysis. The significance level was taken as p0.001. Results. The use of the standard cut-off value of 5000 U/ml of the CA-62 tumor marker makes it possible to achieve 97% sensitivity with 95% specificity in stage I BC. The combination of tumor markers CA-62 and CA 15-3 allows achieving 100% specificity in differentiation of BC and benign breast hyperplasia. The use of the CA-62 marker (6500 U/ml) in the gray zone of PSA 2.510 ng/ml improves the accuracy of detecting PC in biopsy from 35 to 93.1% with 90% sensitivity and 97% specificity. The use of a combination of tumor markers (CA-625000 U/ml, CYFRA 21-12.5 ng/ml and CEA5 ng/ml) will allow the doctor to improve the efficiency of differentiating lung cancer from chronic obstructive pulmonary disease. The combined use of markers (CEA3.5 ng/ml) and (CA-625000 U/ml) achieves 100% specificity with 97% sensitivity in detecting early stages of CRC. Conclusion. The article shows the possibilities of using the CA-62 marker, as well as new algorithms for the detection and differentiation of early stages of BC, PC, non-small cell lung cancer and CRC and benign neoplasms using the CA-62 marker in primary diagnosis. The use of the CA-62 tumor marker or its combination with other diagnostic methods can be a useful strategy for a comprehensive assessment of the risk of malignant neoplasms and increasing the diagnostic sensitivity of detecting early stages of cancer.https://consilium.orscience.ru/2075-1753/article/viewFile/622995/138829clia-ca-62 immunochemiluminescent assaycarcinomatumor marker ca-62interpretation of resultsearly stagesca 15-3psaceacyfra 21-1 |
| spellingShingle | Janneta R. Tcherkassova Sergei A. Tsurkan Anna I. Prostyakova Nikolai V. Suganov Alexander M. Boroda Albina I. Khamitova Alexander P. Roytman Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results Consilium Medicum clia-ca-62 immunochemiluminescent assay carcinoma tumor marker ca-62 interpretation of results early stages ca 15-3 psa cea cyfra 21-1 |
| title | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results |
| title_full | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results |
| title_fullStr | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results |
| title_full_unstemmed | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results |
| title_short | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results |
| title_sort | practical application of the ca 62 tumor marker in the initial diagnosis of oncological disease of epithelial origin assistance to the doctor in interpreting the results |
| topic | clia-ca-62 immunochemiluminescent assay carcinoma tumor marker ca-62 interpretation of results early stages ca 15-3 psa cea cyfra 21-1 |
| url | https://consilium.orscience.ru/2075-1753/article/viewFile/622995/138829 |
| work_keys_str_mv | AT jannetartcherkassova practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT sergeiatsurkan practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT annaiprostyakova practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT nikolaivsuganov practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT alexandermboroda practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT albinaikhamitova practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults AT alexanderproytman practicalapplicationoftheca62tumormarkerintheinitialdiagnosisofoncologicaldiseaseofepithelialoriginassistancetothedoctorininterpretingtheresults |